Reported 2 days ago
H.C. Wainwright has reaffirmed a 'Buy' rating for Atai Life Sciences N.V. (NASDAQ: ATAI) with a price target of $15, following a meeting between the firm and CEO Srinivas Rao. The company is positioned to thrive in the psychedelics sector, bolstered by promising clinical data, particularly for its BPL-003 program. The increasing interest in psychedelic therapies, highlighted by AbbVie's recent acquisition in the field, suggests a strong growth trajectory for Atai.
Source: YAHOO